LifeStance Health Group (NASDAQ:LFST) Upgraded at UBS Group

LifeStance Health Group (NASDAQ:LFST - Get Free Report) was upgraded by stock analysts at UBS Group from a "neutral" rating to a "buy" rating in a report released on Tuesday, MarketBeat Ratings reports. The firm currently has a $8.50 target price on the stock. UBS Group's price objective indicates a potential upside of 42.86% from the stock's previous close.

A number of other research analysts have also recently issued reports on the company. KeyCorp assumed coverage on LifeStance Health Group in a research note on Tuesday, April 8th. They issued an "overweight" rating and a $9.00 target price for the company. Canaccord Genuity Group began coverage on LifeStance Health Group in a research note on Thursday, April 3rd. They set a "buy" rating and a $8.00 target price for the company. Finally, William Blair restated an "outperform" rating on shares of LifeStance Health Group in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, LifeStance Health Group presently has an average rating of "Moderate Buy" and an average price target of $8.50.

LifeStance Health Group Trading Up 0.7%

LFST traded up $0.04 during mid-day trading on Tuesday, hitting $5.95. The stock had a trading volume of 1,492,548 shares, compared to its average volume of 1,590,872. The stock's fifty day simple moving average is $6.32 and its 200-day simple moving average is $7.12. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -22.88 and a beta of 1.30. LifeStance Health Group has a 1-year low of $4.64 and a 1-year high of $8.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.32 and a quick ratio of 1.32.

Insider Activity at LifeStance Health Group

In other news, insider Lisa K. Miller sold 18,845 shares of the business's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.90, for a total value of $130,030.50. Following the sale, the insider now owns 339,810 shares of the company's stock, valued at $2,344,689. The trade was a 5.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 3.20% of the stock is owned by insiders.

Institutional Investors Weigh In On LifeStance Health Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in LFST. JPMorgan Chase & Co. grew its holdings in shares of LifeStance Health Group by 13.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 94,636 shares of the company's stock valued at $662,000 after acquiring an additional 10,894 shares in the last quarter. SG Americas Securities LLC grew its stake in LifeStance Health Group by 65.7% in the fourth quarter. SG Americas Securities LLC now owns 90,355 shares of the company's stock valued at $666,000 after purchasing an additional 35,823 shares in the last quarter. Blue Trust Inc. increased its position in shares of LifeStance Health Group by 124.4% during the 4th quarter. Blue Trust Inc. now owns 3,828 shares of the company's stock worth $27,000 after purchasing an additional 2,122 shares during the last quarter. R Squared Ltd bought a new stake in shares of LifeStance Health Group during the 4th quarter worth approximately $80,000. Finally, Jennison Associates LLC boosted its holdings in shares of LifeStance Health Group by 278.4% in the 4th quarter. Jennison Associates LLC now owns 8,086,380 shares of the company's stock valued at $59,597,000 after buying an additional 5,949,438 shares during the last quarter. 85.50% of the stock is owned by institutional investors.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.